Technology
Health
Pharmaceutical

Forty Seven

$8.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (1.14%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Forty Seven and other stocks, options, ETFs, and crypto commission-free!

About FTSV

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. Read More The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.

Employees
57
Headquarters
Menlo Park, California
Founded
2014
Market Cap
275.74M
Price-Earnings Ratio
Dividend Yield
Average Volume
541.38K
High Today
$9.06
Low Today
$8.71
Open Price
$8.81
Volume
361.47K
52 Week High
$23.83
52 Week Low
$8.27

Collections

Technology
Health
Pharmaceutical
Cancer Prevention
Medical
2018 IPO
US
North America

FTSV Earnings

-$0.74
-$0.67
-$0.61
-$0.54
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.72 per share
Actual
Expected Aug 12, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.